TENOFOVIR ALAFENAMIDE ORAL TABLET
Clinical Criteria Summary
Exclusion Criteria
- Patient prescribed combination product containing tenofovir disoproxil fumarate or tenofovir alafenamide fumarate for HBV and/or HIV infection
- Inclusion Criteria (Must meet at least one)
- Patient with calculated CrCl or eGFR of 15-59 mL/min or has end stage renal disease (ESRD) and is receiving dialysis
- Patient prescribed concomitant nephrotoxic medications (eg: ACE-inhibitors, calcineurin inhibitors, certain chemotherapy agents, diuretics, etc.)
- Patient at risk of fracture or with evidence of bone mineral destruction (including, but not limited to: active treatment for osteoporosis or osteopenia, history of stress fracture, oral glucocorticoid use within past 3 months at a prednisolone dose ≥7.5 mg daily, currently smoking, etc.)
Dosage and Administration
- One 25 mg tablet orally once daily taken with food
Dosing Considerations
- No dose adjustment is needed for patients with a CrCl 15-59 mL/min OR CrCl <15mL/min AND receiving hemodialysis
- Not recommended in patients with ESRD (CrCl < 15 mL/min who are NOT receiving dialysis)